These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 39062986)

  • 21. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
    Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
    Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current state and future prospects of CAR T-cell therapy for myeloid malignancies].
    Saito S
    Rinsho Ketsueki; 2024; 65(7):634-643. PubMed ID: 39098014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
    Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
    Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.
    Huang Y; Qin Y; He Y; Qiu D; Zheng Y; Wei J; Zhang L; Yang DH; Li Y
    Drug Resist Updat; 2024 May; 74():101082. PubMed ID: 38569225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukapheresis for CAR-T cell production and therapy.
    Pessach I; Nagler A
    Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
    Yang Z; Wang Y
    Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.